Investigational drug · Phase 2
DISC-3405
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Polycythemia Vera (PV).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "DISC-3405"
First trial start
2025
Aug 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DISC-3405", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polycythemia Vera (PV)
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "DISC-3405" as an intervention, largest first.
Disc Medicine, IncIndustry
NCT06050915 · 64 participants · Start Oct 3, 2023 · Primary completion Jul 9, 2024
Drug: DISC-3405; DISC-3405 and 2 more · For: Healthy Volunteer
Sites: Lincoln, Nebraska
- A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Active, not recruiting
Disc Medicine, IncIndustry
NCT06985147 · 60 participants (planned) · Start Aug 12, 2025 · Primary completion Jul 2027
Drug: DISC-3405 · For: Polycythemia Vera (PV)
Sites: Phoenix, Arizona; Los Angeles, California; Newport Beach, California · 15 sites in all
Disc Medicine, IncIndustry
NCT07187973 · 24 participants (planned) · Start Jan 6, 2026 · Primary completion Jun 2027
Drug: DISC-3405 · For: Sickle Cell Disease
Sites: Birmingham, Alabama; San Francisco, California; Atlanta, Georgia · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of DISC-3405, a Novel Recombinant Humanized Monoclonal Antibody Targeting TMPRSS6, in Adult Healthy Volunteers.
Liu G, Howell H, Carden MA, et al. · J Clin Pharmacol 2026
Also in development for Polycythemia Vera (PV)
- FlonoltinibPhase 34 trials
Chengdu Zenitar Biomedical Technology Co., Ltd · MF, MF,PMF,PPV-MF,PET-MF, Polycythemia Vera (PV)
- Extended PhasePhase 21 trial
Chengdu Zenitar Biomedical Technology Co., Ltd · Polycythemia Vera (PV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.